As of 2025-05-22, the EV/EBITDA ratio of Esperion Therapeutics Inc (ESPR) is -8.72. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. ESPR's latest enterprise value is 347.38 mil USD. ESPR's TTM EBITDA according to its financial statements is -39.86 mil USD. Dividing these 2 quantities gives us the above ESPR EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 9.4x - 14.7x | 11.6x |
| Forward P/E multiples | 17.5x - 34.4x | 25.8x |
| Fair Price | (2.78) - (0.55) | (1.94) |
| Upside | -426.2% - -164.5% | -327.0% |
| Date | EV/EBITDA |
| 2025-05-20 | -8.99 |
| 2025-05-19 | -8.77 |
| 2025-05-16 | -8.46 |
| 2025-05-15 | -8.34 |
| 2025-05-14 | -8.10 |
| 2025-05-13 | -8.36 |
| 2025-05-12 | -8.45 |
| 2025-05-09 | -8.44 |
| 2025-05-08 | -8.91 |
| 2025-05-07 | -8.80 |
| 2025-05-06 | -9.32 |
| 2025-05-05 | -9.70 |
| 2025-05-02 | -9.89 |
| 2025-05-01 | -9.37 |
| 2025-04-30 | -9.44 |
| 2025-04-29 | -9.25 |
| 2025-04-28 | -8.99 |
| 2025-04-25 | -9.05 |
| 2025-04-24 | -8.86 |
| 2025-04-23 | -9.19 |
| 2025-04-22 | -9.10 |
| 2025-04-21 | -8.71 |
| 2025-04-17 | -9.20 |
| 2025-04-16 | -9.27 |
| 2025-04-15 | -9.43 |
| 2025-04-14 | -9.44 |
| 2025-04-11 | -9.55 |
| 2025-04-10 | -9.25 |
| 2025-04-09 | -9.70 |
| 2025-04-08 | -9.74 |
| 2025-04-07 | -10.44 |
| 2025-04-04 | -10.59 |
| 2025-04-03 | -10.89 |
| 2025-04-02 | -11.39 |
| 2025-04-01 | -11.48 |
| 2025-03-31 | -11.63 |
| 2025-03-28 | -11.93 |
| 2025-03-27 | -12.48 |
| 2025-03-26 | -12.58 |
| 2025-03-25 | -12.83 |
| 2025-03-24 | -13.13 |
| 2025-03-21 | -12.88 |
| 2025-03-20 | -12.53 |
| 2025-03-19 | -12.78 |
| 2025-03-18 | -12.33 |
| 2025-03-17 | -12.13 |
| 2025-03-14 | -11.93 |
| 2025-03-13 | -11.93 |
| 2025-03-12 | -12.03 |
| 2025-03-11 | -12.18 |